Pharmaids Pharmaceuticals Ltd

Pharmaids Pharmaceuticals announced its financial results for the quarter ending December 2024, highlighting significant growth in net sales at Rs 9.95 crore, driven by strong product demand. The company achieved its highest Debtors Turnover Ratio in recent periods, although it faced challenges with a low operating profit margin.

Pharmaids Pharmaceuticals, a microcap pharmaceutical company, has reported a positive financial performance in the second quarter of fiscal year 2024-2025. The company's net sales have increased by 260.8% and the debtors turnover ratio has improved. However, the operating cash flow has been consistently declining, which may be a concern for investors.

Pharmaids Pharmaceuticals, a microcap pharmaceutical company, reached a 52-week high on November 13th, 2024, trading at Rs.87.46. Despite underperforming the sector today, the stock opened with a gain of 4.99%, showing a positive trend. With a significant increase of 87.05% in the past year, the company has potential for growth in the pharmaceutical industry.

Pharmaids Pharmaceuticals, a microcap pharmaceutical company, has seen a remarkable 153.88% increase in stock returns over the past 11 days, reaching an all-time high of Rs.87.46 on November 13th, 2024. Despite a 'Strong Sell' rating from MarketsMOJO, the stock has outperformed the sector and is trading above all its moving averages. It has also shown a significant increase in performance compared to the Sensex.

Pharmaids Pharmaceuticals, a microcap pharmaceutical company, has seen a surge in its stock price, reaching a 52-week high of Rs.83.3 on November 12, 2024. Despite a 'Strong Sell' rating from MarketsMOJO, the stock has outperformed the sector by 4.88% and has been trading above its moving averages. It has also shown a strong performance compared to the Sensex, with a 80.07% increase in the past year.

Pharmaids Pharmaceuticals, a microcap pharmaceutical company, has seen a significant increase in stock price, reaching an all-time high of Rs.80.9 on November 12, 2024. Despite a 'Strong Sell' rating from MarketsMOJO, the stock has outperformed the sector by 1.86% and has been on a 10-day gaining streak with a 134.83% increase. The stock is trading above its moving averages and has shown a remarkable 80.07% increase in the past year, indicating strong performance and potential for growth in the pharmaceutical industry. Investors are advised to conduct their own research before making any investment decisions.

Pharmaids Pharmaceuticals, a microcap company in the pharmaceuticals and drugs industry, has reached a new milestone with its stock price hitting a 52-week high of Rs.79.34 on November 11, 2024. Despite being rated as a 'Strong Sell' by MarketsMOJO, the company has outperformed the sector by 4.75% and has been on a consecutive gain streak for the past 9 days. It is currently trading higher than its moving averages and has shown a significant 1-year performance of 80.07%, highlighting its strong potential for growth.

Pharmaids Pharmaceuticals, a microcap pharmaceutical company, has seen a surge in its stock price, reaching an all-time high of Rs. 79.34 on November 11, 2024. Despite being rated as a 'Strong Sell' by MarketsMOJO, the company has outperformed the sector by 4.99% and has been on a consecutive gain for 9 days.

Pharmaids Pharmaceuticals, a microcap company in the pharmaceuticals and drugs industry, has hit a 52-week low on October 25th, 2024. MarketsMOJO has given it a Strong Sell rating. The stock has underperformed the sector by -2.54% and is currently trading below its moving averages. In the past year, it has seen a negative return of -31.99%. Investors should monitor its performance closely.

Pharmaids Pharmaceuticals, a microcap pharmaceutical company, has hit a 52-week low on October 24th with its stock price dropping to Rs. 32.68. The stock has been given a 'Strong Sell' rating by MarketsMOJO due to its consecutive downward trend for the past 3 days and a total decline of -12.11%. It is currently trading below all its moving averages and has had a negative 1-year performance compared to the Sensex. Investors should carefully consider this information before making any investment decisions.

Pharmaids Pharmaceuticals, a microcap pharmaceutical company, has hit a 52-week low on October 22, 2024, with a Strong Sell rating from MarketsMOJO. The stock has underperformed the sector by -7.11% and has shown high volatility. It has been trading below its moving averages and has a negative performance of -26.39% in the past year.

Pharmaids Pharmaceuticals, a microcap company in the pharmaceutical industry, reported flat financial results for the quarter ending March 2024. Despite receiving a 'Strong Sell' call from MarketsMOJO, the company remains a key player in the market and is focused on improving its performance. Investors are advised to monitor the company's progress and consider MarketsMOJO's call when evaluating the stock.